Halozyme Therapeutics, Inc.
http://www.halozyme.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Halozyme Therapeutics, Inc.
Finance Watch: Certain Offerings Find Their Way To Investors In Tough Market
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Dr Reddy’s Follows Viatris With Second US Nexavar Rival
Hot on the heels of the first US generic Nexavar launch by Viatris, Dr Reddy’s has followed with a second sorafenib rival. The product represents the latest in a string of significant US launches for the Indian company.
Jardiance, Trajenta Wins: Boehringer Takes Rough With Smooth In India
Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?
Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Antares Pharma, Inc.